Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study
Journal of the American Heart Association · 03.01.2023 · 12 (1)
DOI: 10.1161/jaha.122.028050 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 03.01.2023. Verfasst von Daan C H van Dorst und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute Erasmus MC University Medical Center Rotterdam The Netherlands. Hauptthemen laut MEDLINE: Hypertension, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Anti‐cancer vascular endothelial growth factor inhibitors (VEGFI) frequently induce a rise in blood pressure (BP). The most effective treatment of this BP rise is currently unknown, and risk factors and its association with survival remain inconclusive. Methods and Results Baseline characteristics and BP readings were retrospectively collected from oncology patients who received oral VEGFI treatment (sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, or cabozantinib). Risk factors for a clinically relevant BP rise (increase of ≥20 mm Hg in systolic BP or ≥10 mm Hg in diastolic BP) were investigated via logistic regression (relative), efficacy of antihypertensives via unpaired t‐tests, and association of BP rise with survival via Cox regression analysis. In total, 162 (47%) of 343 included patients developed a clinically relevant BP rise ≥7 days after VEGFI treatment initiation. Both calcium channel blockers and renin‐angiotensin system inhibitors effectively reduced systolic BP (−24.1 and −18.2 mm Hg, respectively) and diastolic BP (−12.0 and −11.0 mm Hg, respectively). Pazopanib therapy (odds ratio, 2.71 [95% CI, 1.35–5.42; P =0.005], compared with sorafenib) and estimated glomerular filtration rate
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Erasmus MC Cancer Institute Erasmus MC University Medical Center Rotterdam The Netherlands.
- Division of Vascular Medicine and Pharmacology, Department of Internal Medicine Erasmus MC University Medical Center Rotterdam The Netherlands.
- Department of Hospital Pharmacy Erasmus MC University Medical Center Rotterdam The Netherlands.
ORCID-Profile: Daan C H van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, A H Jan Danser, Ron H J Mathijssen, Jorie Versmissen
Zitieren
APA
van Dorst, D. C. H., Kabadayi, S., Oomen-de Hoop, E., Danser, A. H. J., Mathijssen, R. H. J., & Versmissen, J. (2023). Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association, 12(1). https://doi.org/10.1161/jaha.122.028050
Vancouver
van Dorst DCH, Kabadayi S, Oomen-de Hoop E, Danser AHJ, Mathijssen RHJ, Versmissen J. Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association. 2023;12(1). doi:10.1161/jaha.122.028050
BibTeX
@article{vanDorst2023,
author = {van Dorst, Daan C H and Kabadayi, Sumeyye and Oomen-de Hoop, Esther and Danser, A H Jan and Mathijssen, Ron H J and Versmissen, Jorie},
title = {Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study},
journal = {Journal of the American Heart Association},
year = {2023},
volume = {12},
number = {1},
doi = {10.1161/jaha.122.028050}
}
EUVIMED